Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-...

Full description

Saved in:
Bibliographic Details
Published in:Blood Cancer J
Main Authors: Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A., Wang, Xuewei, Riggs, Daniel L., Porter, Brooke, Ahmann, Jonathan M., de Campos, Cecilia Bonolo, Braggio, Esteban, Bergsagel, P. Leif, Stewart, A. Keith
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6370766/
https://ncbi.nlm.nih.gov/pubmed/30741931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0173-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items